Peptides Explained: The Billion-Dollar Drug Revolution

Peptides are amino acid chains that act as targeted keys to unlock specific cellular locks, offering precise therapeutic effects. Once banned by the FDA in 2023, seven are being reconsidered for legalization in July 2024. They can address weight loss, skin, muscle recovery, sleep, cognition, and fertility—but require medical oversight and lifestyle changes to work effectively.

What Peptides Are and How They Work

Peptides are targeted amino acid chains

Peptides are small fragments of amino acids (the building blocks of proteins) designed to target specific cellular receptors with precision. Unlike small-molecule drugs that act broadly throughout the body, peptides function like a specific key fitting into a specific lock, minimizing side effects and off-target effects.

Historical context: insulin was the first peptide drug

Insulin, isolated in 1921, was the first peptide used in medicine. Lupron (1985) followed as another peptide that shut down testosterone production for prostate cancer patients. Both demonstrated that peptides could have highly specific endocrine and metabolic effects.

Why Peptides Exploded Now: The Regulatory Story

Myriad Genetics case removed pharma incentive to develop unprofitable compounds

In 2013, the Supreme Court ruled that naturally occurring compounds (like genes) cannot be patented. This eliminated pharmaceutical companies' financial incentive to develop promising peptides they couldn't monetize, leaving them stuck in development limbo.

2014 compounding pharmacy regulations created legal pathway

After a 2012 fungal meningitis outbreak from contaminated compounding pharmacies, the FDA introduced new regulations. Crucially, they allowed compounding pharmacies to make peptides on a specific approved list (Category 1), enabling physicians to prescribe them legally to patients.

FDA reversed course in 2023, banning 19 peptides overnight

In 2023, the FDA reclassified 19 popular peptides from Category 1 (compoundable) to Category 2 (forbidden), citing insufficient safety data despite years of safe use. Compounding pharmacies received notification emails that they could no longer produce these compounds, cutting off patient access immediately.

Pharma likely lobbied FDA to eliminate competition

Dr. Tatem estimates 110% probability that pharmaceutical companies influenced the 2023 ban because peptides, though not direct competitors, redirect patient spending away from expensive prescription drugs. The FDA commissioner has tweeted more about cracking down on compounded GLP-1 medications than about diabetes or heart disease in his entire tenure.

The Gray Market and Quality Control Crisis

Research-use-only peptides flood the market post-ban

After the 2023 ban, companies began selling peptides labeled 'for research use only' to circumvent FDA jurisdiction. This mirrors alcohol prohibition—banning drove the market underground. Without quality control, these products are contaminated, misdosed, or counterfeit, like 'gas station sushi.'

Compounding pharmacies offer safer, legal alternative

Compounding pharmacies operate under 503A regulations and provide standardized, quality-controlled formulations with prescriptions. They enable personalized dosing (e.g., microdosing tirzepatide throughout the week instead of one large weekly dose), which many patients tolerate better.

Key Peptides and Their Effects

BPC-157: healing and tissue repair

BPC-157 is a synthetic version of a naturally occurring gut peptide that enhances blood vessel growth in injured areas. In animal models, it healed completely transected Achilles tendons. It has an extraordinarily high safety profile—the LD50 (lethal dose for 50% of subjects) has never been determined because it is so well tolerated.

GLP-1 drugs (semaglutide, tirzepatide): weight loss and metabolic health

GLP-1 peptides slow gastric emptying, reducing hunger and caloric intake. Tirzepatide produces more weight loss per milligram than any other available drug. A patient with low sperm count increased his count 10-fold after losing 100 lb on tirzepatide, restoring fertility.

Retatrutide: triple-receptor agonist (next generation)

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. It produces 20–25% total body weight loss in short timeframes and dramatically improves liver health by reducing visceral fat. Dr. Tatem predicts it will be a trillion-dollar drug. Bodybuilders have already adopted it from research-use-only sources.

GHK-Cu: skin regeneration and anti-aging

GHK-Cu is a copper tripeptide that decreases with age. Applied topically as a cream, it increases collagen and elastin production, improving skin complexion and reducing visible signs of aging. It is currently available as a topical formulation because it is regulated differently than injectable forms.

C-Max: cognitive enhancement and recovery

C-Max is a seven-amino acid peptide studied in Russia for traumatic brain injury and stroke recovery. Administered intranasally, it upregulates cognitive factors and improves mental performance. It is expected to be relegalised in July 2024.

MOTS-c: exercise in a vial

MOTS-c improves VO2 max and exercise tolerance by upregulating ATP (cellular energy) production. It is one of seven peptides expected to be relegalised in July 2024.

Melanotan II: tanning and sexual function

Melanotan II is a melanocortin receptor agonist that produces a deep tan with minimal UV exposure and significantly enhances erectile function. A derivative, PT-141 (bremelanotide), is commercially available and provides sexual benefits without tanning.

Tesamorelin: visceral fat reduction

Tesamorelin boosts growth hormone and is uniquely effective at stripping abdominal (visceral) fat. It is commercially available by prescription. However, weight returns if lifestyle changes are not maintained.

CJC-1295 and Ipamorelin: growth hormone secretagogues

These two peptides stimulate natural growth hormone release through different mechanisms (GHRH and ghrelin receptor pathways). Combined, they are potent for muscle building, fat loss, tissue healing, and skin/hair/nail quality. They are often stacked together.

Epithalon: telomerase activation and aging

Epithalon enhances telomerase, the enzyme that repairs telomeres (the protective caps on DNA that shorten with age). Some view it as a 'fountain of youth,' though Dr. Tatem is skeptical. It shows benefits for circadian rhythm regulation. Expected to be relegalised in July 2024.

DSIP and Selank: sleep and circadian rhythm

DSIP regulates circadian rhythm and is expected to be relegalised in July 2024. Selank calms the nervous system about an hour before sleep and promotes deep delta-wave brain activity. Both address sleep quality and recovery.

Growth hormone (somatotropin): broad anti-aging effects

Growth hormone improves sleep quality, hair/skin/nail quality, tissue healing, muscle building, and fat loss. However, excessive doses cause insulin resistance, acromegaly (irreversible facial bone growth), potential cancer acceleration, and hand numbness from joint effusions.

IGF-1 LR3: muscle growth (limited)

IGF-1 LR3 is the longer-acting form of insulin-like growth factor 1 (downstream of growth hormone). While it can contribute to muscle mass in higher doses, it is not an independent muscle-builder—resistance training is still essential.

FDA Relegalisation: July 2024 Decision

Seven peptides being reconsidered for Category 1 status

In April 2024, the FDA announced it would consider relegalising seven peptides in July 2024: BPC-157, TB-500, KPV, MOTS-c, DSIP, epithalon, and C-Max. This reversal follows pressure from the current administration and RFK, who characterised the 2023 ban as illegal.

How to Take Peptides and Dosing

Peptides cannot be taken orally (with rare exceptions)

Because peptides are amino acid chains, the gut breaks them down into individual amino acids, making them indistinguishable from food protein. The only major exception is BPC-157, which has an oral formulation. Most peptides must be injected subcutaneously (under the skin) or intramuscularly.

Subcutaneous injection: 'pinch an inch'

Subcutaneous injection means injecting just under the skin (e.g., in the belly). Patients pinch an inch of skin and inject with a small needle. This is the standard administration route for most peptides.

Compounded vials allow custom microdosing

Compounded peptides come in vials that patients draw up with a syringe, enabling flexible dosing. For example, instead of one large tirzepatide dose weekly (which causes hunger return by week's end), patients can microdose multiple times per week for better tolerance and sustained appetite suppression.

Commercial pens (e.g., Mounjaro) offer convenience but fixed dosing

Brand-name peptide pens like Mounjaro (tirzepatide) are auto-injectors with preset doses, approved for once-weekly administration. They are convenient but lack the flexibility of compounded formulations.

Trade-offs and Safety Concerns

Rapid weight loss causes muscle loss without intervention

GLP-1 drugs create a large caloric deficit, triggering catabolism (tissue breakdown). The body breaks down both fat and muscle. Muscle is metabolically critical, so rapid weight loss without resistance training and muscle-preserving interventions (e.g., testosterone, myostatin inhibitors) is counterproductive.

Growth hormone abuse causes irreversible acromegaly

Excessive growth hormone doses cause bones to continue growing at specific joints, creating an irreversible facial deformity characteristic of long-term abuse. This is a permanent cosmetic and structural change.

Growth hormone may increase cancer risk

While growth hormone has not been shown to cause new cancers, it could theoretically accelerate existing malignancies. This remains a theoretical concern requiring caution in patients with cancer history.

Weight regain after stopping GLP-1 without lifestyle change

If patients discontinue GLP-1 drugs and do not maintain diet and exercise changes, they regain most or all of the weight. Peptides are tools, not replacements for lifestyle modification. Some patients maintain weight loss at lower maintenance doses.

Research-use-only peptides lack quality assurance

Gray-market peptides have no standardised manufacturing, sterility testing, or potency verification. Contamination, misdosing, and counterfeit products are common risks.

Clinical Applications and Patient Outcomes

Infertility reversal through weight loss and metabolic repair

Young men with obesity, insulin resistance, and low sperm counts often have hormonal dysfunction secondary to metabolic disease, not primary hypogonadism. Using tirzepatide to achieve 100 lb weight loss, combined with exercise and diet, restored one patient's sperm count 10-fold to normal range, enabling natural conception.

Liver health improvements with retatrutide

Retatrutide produces the best liver health improvements ever observed in clinical trials by reducing visceral fat accumulation in the liver and reducing inflammation (NASH).

The Peptide Industry and Market Size

Peptide market rivals AI industry in revenue

Semaglutide and tirzepatide alone generate over $55 billion in annual revenue. The entire top-four AI companies combined generate $58–62 billion. Peptides, without counting research-use-only or compounded markets, are approaching parity with the AI industry.

Retatrutide predicted to be a trillion-dollar drug

Dr. Tatem predicts retatrutide will become a trillion-dollar drug due to its superior efficacy, broad metabolic benefits, and massive addressable market (obesity, diabetes, liver disease).

Broader Health Implications

Male fertility crisis: sperm count declining since 1973

Total modal sperm count has declined exponentially since 1973, with progressive deterioration in sperm quality, motility, and concentration. This is documented across multiple studies and is real, not a measurement artifact.

Metabolic disease is the root cause of most chronic illness

Obesity and insulin resistance drive cardiac disease, erectile dysfunction, cancer, and other major health conditions. Peptides like GLP-1 drugs could prevent metabolic disease at scale, potentially transforming public health.

Obesity rates in the US: 40–70% depending on BMI cutoff

Eating greens and going to the gym are not working as population-level interventions. Food deserts, calorie-dense but nutritionally poor food, and systemic factors require pharmacological tools alongside lifestyle change.

The Enhanced Games and Future of Sport

Enhanced Games: legalized doping with medical oversight

The Enhanced Games (Las Vegas, May 21–24, 2024) allow athletes to use FDA-approved performance-enhancing drugs under strict medical supervision. Prize money: $250,000 for first place, $1 million for world records. Olympic athletes receive no prize money, only sponsorships.

40% of Olympic athletes may already use banned substances

According to WADA data, up to 40% of Olympic-level athletes have used or are currently using banned substances. The Enhanced Games aims to create a transparent, medically supervised alternative.

Dr. Tatem's Personal Practice and Philosophy

Dr. Tatem specializes in men's health: hormones, ED, fertility

Dr. Tatem's urology subspecialty focuses on low testosterone, erectile dysfunction, Peyronie's disease, male infertility, and post-prostate-cancer incontinence. He performs penile implant surgery (about 1,100–1,200 procedures), which restores erectile function via an internal hydraulic pump hidden in the scrotum.

30 million US men have erectile dysfunction

Erectile dysfunction affects more men than Australia's population. Oral medications fail in 15% of cases on first use, leaving millions needing alternative treatments like penile implants.

Medical training's toll and recovery through health prioritization

Dr. Tatem worked 80–100 hours per week during 5 years of surgical training, resulting in low testosterone, high cortisol, and physical/psychological deterioration. After diagnosis and recovery, he committed to practising what he preaches: prioritising his own health, family, and patients.

Practical Guidance for Patients

Three categories of peptide access

Category 1: legally available from commercial pharmacies (GLP-1s, PT-141, oxytocin). Category 2: expected to be relegalised in July 2024 (BPC-157, TB-500, etc.). Category 3: research-use-only (unregulated, not recommended).

Consult your doctor before pursuing peptides

Patients should educate themselves, identify their health problems, and discuss peptides as one tool among many (diet, exercise, hormones, other medications). Peptides are not shortcuts—they require lifestyle changes to work optimally.

Avoid research-use-only peptides due to quality and safety risks

Gray-market peptides lack standardisation, sterility testing, and potency verification. Quality control is absent. Patients should wait for legal pathways or work with compounding pharmacies under physician supervision.

Peptides are tools, not replacements for lifestyle

GLP-1 drugs are the closest thing to a shortcut, but they do not replace gym work, resistance training, or nutrition. Muscle preservation requires deliberate effort. There are no true shortcuts in health.

Notable quotes

The question isn't what can peptides do, it's what can't they do. — Dr. Alex Tatem
This is going to be a trillion-dollar drug when it comes out. — Dr. Alex Tatem (on retatrutide)
There are no real shortcuts. My alarm still went off at 4:45 this morning so I could hit the gym. — Dr. Alex Tatem

Action items

  • Educate yourself on the three categories of peptide access (commercial, relegalised, research-only) before pursuing any peptide.
  • Consult with a physician knowledgeable about peptides to identify your specific health problems and determine if a peptide is an appropriate tool.
  • Avoid purchasing research-use-only peptides due to lack of quality control, sterility testing, and potency verification.
  • If pursuing GLP-1 drugs or other weight-loss peptides, commit to resistance training and nutrition changes to preserve muscle mass during fat loss.
  • Monitor the FDA's July 2024 decision on the seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, epithalon, C-Max) for potential relegalisation and compounding pharmacy availability.
  • Work with a compounding pharmacy under physician supervision for personalised dosing and quality assurance once peptides are relegalised.
  • Subscribe to Dr. Alex Tatem's YouTube channel for ongoing education on peptides, hormones, and men's health.
The Diary Of A CEO
1 hr 30 min video
3 min read
Peptides Explained: The Billion-Dollar Drug Revolution
You just saved 1 hr 27 min.
The big takeaway
Peptides are amino acid chains that act as targeted keys to unlock specific cellular locks, offering precise therapeutic effects. Once banned by the FDA in 2023, seven are being reconsidered for legalization in July 2024. They can address weight loss, skin, muscle recovery, sleep, cognition, and fertility—but require medical oversight and lifestyle changes to work effectively.
What Peptides Are and How They Work
Peptides are targeted amino acid chains
Peptides are small fragments of amino acids (the building blocks of proteins) designed to target specific cellular receptors with precision. Unlike small-molecule drugs that act broadly throughout the body, peptides function like a specific key fitting into a specific lock, minimizing side effects and off-target effects.
Historical context: insulin was the first peptide drug
Insulin, isolated in 1921, was the first peptide used in medicine. Lupron (1985) followed as another peptide that shut down testosterone production for prostate cancer patients. Both demonstrated that peptides could have highly specific endocrine and metabolic effects.
1921
Insulin isolated—first peptide drug
1985
Lupron approved—endocrine-specific peptide
2013
Myriad Genetics case: Supreme Court rules natural compounds cannot be patented
2014
FDA compounding pharmacy regulations allow peptide production
2023
FDA bans 19 popular peptides overnight
July 2024
FDA considers relegalizing 7 peptides
Peptide timeline: from discovery to regulatory upheaval
Why Peptides Exploded Now: The Regulatory Story
Myriad Genetics case removed pharma incentive to develop unprofitable compounds
In 2013, the Supreme Court ruled that naturally occurring compounds (like genes) cannot be patented. This eliminated pharmaceutical companies' financial incentive to develop promising peptides they couldn't monetize, leaving them stuck in development limbo.
2014 compounding pharmacy regulations created legal pathway
After a 2012 fungal meningitis outbreak from contaminated compounding pharmacies, the FDA introduced new regulations. Crucially, they allowed compounding pharmacies to make peptides on a specific approved list (Category 1), enabling physicians to prescribe them legally to patients.
FDA reversed course in 2023, banning 19 peptides overnight
In 2023, the FDA reclassified 19 popular peptides from Category 1 (compoundable) to Category 2 (forbidden), citing insufficient safety data despite years of safe use. Compounding pharmacies received notification emails that they could no longer produce these compounds, cutting off patient access immediately.
Pharma likely lobbied FDA to eliminate competition
Dr. Tatem estimates 110% probability that pharmaceutical companies influenced the 2023 ban because peptides, though not direct competitors, redirect patient spending away from expensive prescription drugs. The FDA commissioner has tweeted more about cracking down on compounded GLP-1 medications than about diabetes or heart disease in his entire tenure.
The Gray Market and Quality Control Crisis
Research-use-only peptides flood the market post-ban
After the 2023 ban, companies began selling peptides labeled 'for research use only' to circumvent FDA jurisdiction. This mirrors alcohol prohibition—banning drove the market underground. Without quality control, these products are contaminated, misdosed, or counterfeit, like 'gas station sushi.'
Compounding pharmacies offer safer, legal alternative
Compounding pharmacies operate under 503A regulations and provide standardized, quality-controlled formulations with prescriptions. They enable personalized dosing (e.g., microdosing tirzepatide throughout the week instead of one large weekly dose), which many patients tolerate better.
Key Peptides and Their Effects
BPC-157: healing and tissue repair
BPC-157 is a synthetic version of a naturally occurring gut peptide that enhances blood vessel growth in injured areas. In animal models, it healed completely transected Achilles tendons. It has an extraordinarily high safety profile—the LD50 (lethal dose for 50% of subjects) has never been determined because it is so well tolerated.
GLP-1 drugs (semaglutide, tirzepatide): weight loss and metabolic health
GLP-1 peptides slow gastric emptying, reducing hunger and caloric intake. Tirzepatide produces more weight loss per milligram than any other available drug. A patient with low sperm count increased his count 10-fold after losing 100 lb on tirzepatide, restoring fertility.
Retatrutide: triple-receptor agonist (next generation)
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. It produces 20–25% total body weight loss in short timeframes and dramatically improves liver health by reducing visceral fat. Dr. Tatem predicts it will be a trillion-dollar drug. Bodybuilders have already adopted it from research-use-only sources.
20–25%
Total body weight loss with retatrutide
Retatrutide efficacy in clinical trials and user reports
GHK-Cu: skin regeneration and anti-aging
GHK-Cu is a copper tripeptide that decreases with age. Applied topically as a cream, it increases collagen and elastin production, improving skin complexion and reducing visible signs of aging. It is currently available as a topical formulation because it is regulated differently than injectable forms.
C-Max: cognitive enhancement and recovery
C-Max is a seven-amino acid peptide studied in Russia for traumatic brain injury and stroke recovery. Administered intranasally, it upregulates cognitive factors and improves mental performance. It is expected to be relegalised in July 2024.
MOTS-c: exercise in a vial
MOTS-c improves VO2 max and exercise tolerance by upregulating ATP (cellular energy) production. It is one of seven peptides expected to be relegalised in July 2024.
Melanotan II: tanning and sexual function
Melanotan II is a melanocortin receptor agonist that produces a deep tan with minimal UV exposure and significantly enhances erectile function. A derivative, PT-141 (bremelanotide), is commercially available and provides sexual benefits without tanning.
Tesamorelin: visceral fat reduction
Tesamorelin boosts growth hormone and is uniquely effective at stripping abdominal (visceral) fat. It is commercially available by prescription. However, weight returns if lifestyle changes are not maintained.
CJC-1295 and Ipamorelin: growth hormone secretagogues
These two peptides stimulate natural growth hormone release through different mechanisms (GHRH and ghrelin receptor pathways). Combined, they are potent for muscle building, fat loss, tissue healing, and skin/hair/nail quality. They are often stacked together.
Epithalon: telomerase activation and aging
Epithalon enhances telomerase, the enzyme that repairs telomeres (the protective caps on DNA that shorten with age). Some view it as a 'fountain of youth,' though Dr. Tatem is skeptical. It shows benefits for circadian rhythm regulation. Expected to be relegalised in July 2024.
DSIP and Selank: sleep and circadian rhythm
DSIP regulates circadian rhythm and is expected to be relegalised in July 2024. Selank calms the nervous system about an hour before sleep and promotes deep delta-wave brain activity. Both address sleep quality and recovery.
Growth hormone (somatotropin): broad anti-aging effects
Growth hormone improves sleep quality, hair/skin/nail quality, tissue healing, muscle building, and fat loss. However, excessive doses cause insulin resistance, acromegaly (irreversible facial bone growth), potential cancer acceleration, and hand numbness from joint effusions.
IGF-1 LR3: muscle growth (limited)
IGF-1 LR3 is the longer-acting form of insulin-like growth factor 1 (downstream of growth hormone). While it can contribute to muscle mass in higher doses, it is not an independent muscle-builder—resistance training is still essential.
FDA Relegalisation: July 2024 Decision
Seven peptides being reconsidered for Category 1 status
In April 2024, the FDA announced it would consider relegalising seven peptides in July 2024: BPC-157, TB-500, KPV, MOTS-c, DSIP, epithalon, and C-Max. This reversal follows pressure from the current administration and RFK, who characterised the 2023 ban as illegal.
1
BPC-157
Injury healing & tissue repair
2
TB-500
Blood flow to injured areas
3
KPV
Angiogenesis & tissue repair
4
MOTS-c
VO2 max & exercise tolerance
5
DSIP
Sleep & circadian rhythm
6
Epithalon
Telomerase & aging
7
C-Max
Cognition & brain recovery
Seven peptides under FDA consideration for relegalisation (July 2024)
How to Take Peptides and Dosing
Peptides cannot be taken orally (with rare exceptions)
Because peptides are amino acid chains, the gut breaks them down into individual amino acids, making them indistinguishable from food protein. The only major exception is BPC-157, which has an oral formulation. Most peptides must be injected subcutaneously (under the skin) or intramuscularly.
Subcutaneous injection: 'pinch an inch'
Subcutaneous injection means injecting just under the skin (e.g., in the belly). Patients pinch an inch of skin and inject with a small needle. This is the standard administration route for most peptides.
Compounded vials allow custom microdosing
Compounded peptides come in vials that patients draw up with a syringe, enabling flexible dosing. For example, instead of one large tirzepatide dose weekly (which causes hunger return by week's end), patients can microdose multiple times per week for better tolerance and sustained appetite suppression.
Commercial pens (e.g., Mounjaro) offer convenience but fixed dosing
Brand-name peptide pens like Mounjaro (tirzepatide) are auto-injectors with preset doses, approved for once-weekly administration. They are convenient but lack the flexibility of compounded formulations.
Trade-offs and Safety Concerns
Rapid weight loss causes muscle loss without intervention
GLP-1 drugs create a large caloric deficit, triggering catabolism (tissue breakdown). The body breaks down both fat and muscle. Muscle is metabolically critical, so rapid weight loss without resistance training and muscle-preserving interventions (e.g., testosterone, myostatin inhibitors) is counterproductive.
Growth hormone abuse causes irreversible acromegaly
Excessive growth hormone doses cause bones to continue growing at specific joints, creating an irreversible facial deformity characteristic of long-term abuse. This is a permanent cosmetic and structural change.
Growth hormone may increase cancer risk
While growth hormone has not been shown to cause new cancers, it could theoretically accelerate existing malignancies. This remains a theoretical concern requiring caution in patients with cancer history.
Weight regain after stopping GLP-1 without lifestyle change
If patients discontinue GLP-1 drugs and do not maintain diet and exercise changes, they regain most or all of the weight. Peptides are tools, not replacements for lifestyle modification. Some patients maintain weight loss at lower maintenance doses.
Research-use-only peptides lack quality assurance
Gray-market peptides have no standardised manufacturing, sterility testing, or potency verification. Contamination, misdosing, and counterfeit products are common risks.
Clinical Applications and Patient Outcomes
Infertility reversal through weight loss and metabolic repair
Young men with obesity, insulin resistance, and low sperm counts often have hormonal dysfunction secondary to metabolic disease, not primary hypogonadism. Using tirzepatide to achieve 100 lb weight loss, combined with exercise and diet, restored one patient's sperm count 10-fold to normal range, enabling natural conception.
Before tirzepatide
Low sperm count, infertile
After 100 lb weight loss
10x increase in sperm count, normal range
Patient case: metabolic repair restores fertility
Liver health improvements with retatrutide
Retatrutide produces the best liver health improvements ever observed in clinical trials by reducing visceral fat accumulation in the liver and reducing inflammation (NASH).
The Peptide Industry and Market Size
Peptide market rivals AI industry in revenue
Semaglutide and tirzepatide alone generate over $55 billion in annual revenue. The entire top-four AI companies combined generate $58–62 billion. Peptides, without counting research-use-only or compounded markets, are approaching parity with the AI industry.
Semaglutide + tirzepatide
55 $ billion/year
Top 4 AI companies
60 $ billion/year
Peptide revenue vs. AI industry (2024 estimates)
Retatrutide predicted to be a trillion-dollar drug
Dr. Tatem predicts retatrutide will become a trillion-dollar drug due to its superior efficacy, broad metabolic benefits, and massive addressable market (obesity, diabetes, liver disease).
Broader Health Implications
Male fertility crisis: sperm count declining since 1973
Total modal sperm count has declined exponentially since 1973, with progressive deterioration in sperm quality, motility, and concentration. This is documented across multiple studies and is real, not a measurement artifact.
1973
High sperm density, opaque sample
2045 (projected)
Low sperm density, clear sample
Male fertility trajectory: 50+ year decline
Metabolic disease is the root cause of most chronic illness
Obesity and insulin resistance drive cardiac disease, erectile dysfunction, cancer, and other major health conditions. Peptides like GLP-1 drugs could prevent metabolic disease at scale, potentially transforming public health.
Obesity rates in the US: 40–70% depending on BMI cutoff
Eating greens and going to the gym are not working as population-level interventions. Food deserts, calorie-dense but nutritionally poor food, and systemic factors require pharmacological tools alongside lifestyle change.
40–70%
US obesity rate (depending on BMI definition)
Population-level obesity crisis
The Enhanced Games and Future of Sport
Enhanced Games: legalized doping with medical oversight
The Enhanced Games (Las Vegas, May 21–24, 2024) allow athletes to use FDA-approved performance-enhancing drugs under strict medical supervision. Prize money: $250,000 for first place, $1 million for world records. Olympic athletes receive no prize money, only sponsorships.
Enhanced Games 1st place
250 $ thousand
Enhanced Games world record
1000 $ thousand
Olympic gold medal prize
0 $ (no payment)
Prize money comparison: Enhanced Games vs. Olympics
40% of Olympic athletes may already use banned substances
According to WADA data, up to 40% of Olympic-level athletes have used or are currently using banned substances. The Enhanced Games aims to create a transparent, medically supervised alternative.
Dr. Tatem's Personal Practice and Philosophy
Dr. Tatem specializes in men's health: hormones, ED, fertility
Dr. Tatem's urology subspecialty focuses on low testosterone, erectile dysfunction, Peyronie's disease, male infertility, and post-prostate-cancer incontinence. He performs penile implant surgery (about 1,100–1,200 procedures), which restores erectile function via an internal hydraulic pump hidden in the scrotum.
30 million US men have erectile dysfunction
Erectile dysfunction affects more men than Australia's population. Oral medications fail in 15% of cases on first use, leaving millions needing alternative treatments like penile implants.
30 million
US men with erectile dysfunction
Larger than Australia's population
Medical training's toll and recovery through health prioritization
Dr. Tatem worked 80–100 hours per week during 5 years of surgical training, resulting in low testosterone, high cortisol, and physical/psychological deterioration. After diagnosis and recovery, he committed to practising what he preaches: prioritising his own health, family, and patients.
Practical Guidance for Patients
Three categories of peptide access
Category 1: legally available from commercial pharmacies (GLP-1s, PT-141, oxytocin). Category 2: expected to be relegalised in July 2024 (BPC-157, TB-500, etc.). Category 3: research-use-only (unregulated, not recommended).
Consult your doctor before pursuing peptides
Patients should educate themselves, identify their health problems, and discuss peptides as one tool among many (diet, exercise, hormones, other medications). Peptides are not shortcuts—they require lifestyle changes to work optimally.
Avoid research-use-only peptides due to quality and safety risks
Gray-market peptides lack standardisation, sterility testing, and potency verification. Quality control is absent. Patients should wait for legal pathways or work with compounding pharmacies under physician supervision.
Peptides are tools, not replacements for lifestyle
GLP-1 drugs are the closest thing to a shortcut, but they do not replace gym work, resistance training, or nutrition. Muscle preservation requires deliberate effort. There are no true shortcuts in health.
Worth quoting
"The question isn't what can peptides do, it's what can't they do."
— Dr. Alex Tatem, at [0:30]
"This is going to be a trillion-dollar drug when it comes out."
— Dr. Alex Tatem (on retatrutide), at [0:00]
"There are no real shortcuts. My alarm still went off at 4:45 this morning so I could hit the gym."
— Dr. Alex Tatem, at [50:20]
Try this
Educate yourself on the three categories of peptide access (commercial, relegalised, research-only) before pursuing any peptide.
Consult with a physician knowledgeable about peptides to identify your specific health problems and determine if a peptide is an appropriate tool.
Avoid purchasing research-use-only peptides due to lack of quality control, sterility testing, and potency verification.
If pursuing GLP-1 drugs or other weight-loss peptides, commit to resistance training and nutrition changes to preserve muscle mass during fat loss.
Monitor the FDA's July 2024 decision on the seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, epithalon, C-Max) for potential relegalisation and compounding pharmacy availability.
Work with a compounding pharmacy under physician supervision for personalised dosing and quality assurance once peptides are relegalised.
Subscribe to Dr. Alex Tatem's YouTube channel for ongoing education on peptides, hormones, and men's health.
Made with Glimpse by Wozart
glimpse.wozart.com/v/ek7vvne0
Share this infographic

More like this